About: A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
Creator	Chabalala, Hlupheka Dassarma, Barsha Gilbert Matsabisa, Motlalepula Gilbert, Motlalepula Matsabisa, Motlalepula, G Roy, Somenath Tripathy, Satyajit
Source	Elsevier; Medline; PMC
abstract	The chloroquine (CQ) and its analogue hydroxychloroquine (HCQ) have been used as frontline drugs for treatment and prophylaxis against all types of human malaria worldwide. Since late December 2019, humans have been under threat due to an outbreak of a novel coronavirus (SARS-CoV-2) disease (COVID-19; previously known as 2019-nCoV), since its first reported cases in Wuhan, China [1]. Consequently, the virus infection has been declared a pandemic. While the World is finding expedited approvals for the development of vaccine, which is time dependent, being preventative and not possibly a cure, physicians and countries’ leaders are considering several concerted clinical trials suggesting that this age-old antimalarial drug, CQ/HCQ could be a potent therapeutic agent against COVID-19 infection. Based on accumulating scientific reports, we have highlighted in this review, the different possible modes of action of chloroquine/hydroxychloroquine that could particularly justify its use against viral infections. Considering the global health crisis of the COVID-19 pandemic, the option of using the drugs and repurposing of old drugs in this instance, chloroquine and hydroxychloroquine, specifically, hydroxychloroquine in the treatment of SARS-CoV-2 could be the best choice. CQ/HCQ has diverse modes of action, like alteration of acidic environment inside lysosome, late endosomes, restriction further with endocytosis, exsosome release, phagolysosomal fusion in systematically and subsequently inhibition of cytokine storm in host cell. One or sum of diverse mechanisms might work against the viral infections and help prevent more deaths. Given that there is no cure for COVID-19, the clinical testing of HCQ is urgently needed to ascertain its potency against the virus as this is the current available treatment option. There is still a need to find other innovative drug candidates as other possible candidate to go into clinical evaluation and testing.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.106028
bibo:pmid	32450198
has license	no-cc
sha1sum (hex)	8e68d96538d97f3b97f1f1fabd4fbf8369d9f6e1
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.106028
resource representing a document's title	A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic
has PubMed Central identifier	PMC7243790
has PubMed identifier	32450198
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:8e68d96538d97f3b97f1f1fabd4fbf8369d9f6e1#body_text
is schema:about of	named entity 'attenuate' named entity 'pandemic' named entity 'COVID' named entity 'pandemic' named entity 'CHLOROQUINE' named entity 'APPROACH' named entity 'HYDROXYCHLOROQUINE' named entity 'ACE2' named entity 'response' named entity 'STING' named entity 'viral infection' named entity 'Repurposing' named entity 'Chloroquine' named entity 'Chloroquine' named entity 'SARS-COV-2' named entity 'STING' named entity 'attenuate' named entity 'Chloroquine' named entity 'Hydroxychloroquine' named entity 'chloroquine phosphate' named entity 'control group' named entity 'HCQ' named entity 'Paul Ehrlich' named entity 'cellular receptor' named entity 'high affinity' named entity 'Hydroxychloroquine' named entity 'unprotonated' named entity 'chloroquine' named entity 'spike protein' named entity 'lopinavir' named entity 'SARS-CoV-2' named entity 'TLR' named entity 'bound to plasma proteins' named entity 'chloroquine' named entity 'China' named entity 'lysosomes' named entity 'mechanical ventilation' named entity 'cytosol' named entity 'virus' named entity 'anticancer agent' named entity 'HCQ' named entity 'ritonavir' named entity 'heart rhythm' named entity 'host cell' named entity 'fibroblasts' named entity 'Chloroquine' named entity 'COVID-19 pandemic' named entity 'chemically synthesized' named entity 'gangliosides' named entity 'glycosyltransferases' named entity 'biopsy' named entity 'sialic acids' named entity 'hydroxychloroquine' named entity 'vesicles' named entity 'respiratory failure' named entity 'metastasis' named entity 'glycoproteins' named entity 'CD147' named entity 'primaquine' named entity 'methyl group' named entity 'inducer' named entity 'albumin' named entity 'endosomes' named entity 'viruses' named entity 'angiotensin-converting enzyme 2' named entity 'enveloped viruses' named entity 'Wuhan' named entity 'viral infections' named entity 'CXCL12' named entity 'benzene ring' named entity 'TGN' named entity 'dengue' named entity 'attenuation' named entity 'COVID 19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software